Skip to content
Screener

Acadia Pharmaceuticals ACAD Q4 2025 Annual earnings

Reported February 25, 2026 · After market close

Revenue$284.0MMiss by $8.8M
EPS$1.60Beat by $1.46
Revenue estimate$292.8M
EPS estimate$0.14

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$332.3M
EPS estimate$0.21

Financials

Q4 2025

Income statement

See full
Revenue$284.0M+9.4%
Gross profit$257.8M+8.4%
Operating income$17.4M-88.7%
Net income$273.6M+90.3%
EPS (diluted)$1.61+87.2%

Balance sheet

See full
Cash & equivalents$177.7M-44.4%
Total debt$52.2M+0.4%
Total equity$1.2B+67.5%
Total assets$1.6B+31.7%

Cash flow

See full
CapEx$4.0M+784%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$4.52B+48.0%
Enterprise value$4.39B+57.7%
P/E11.6×-1.9×
P/S4.2×+1.0×

Profitability

See full
Gross margin91.7%+0.2pp
Operating margin9.8%-14.3pp
Net margin36.5%+12.8pp

Returns & leverage

See full
Return on equity39.9%+1.0pp
Debt / equity0×0.0×
Current ratio3.8×+1.5×

Segments

By product

See full
Nuplazid$174.4M+7.1%
Daybue$109.6M+13.3%

By segment

See full
Reportable Segment Aggregation Before Other Operating$284.0M+9.4%

FAQ

When did Acadia Pharmaceuticals report Q4 2025 earnings?
Acadia Pharmaceuticals (ACAD) reported Q4 2025 earnings on February 25, 2026 after market close.
What were Acadia Pharmaceuticals's Q4 2025 revenue and EPS?
Acadia Pharmaceuticals reported revenue of $284.0M and eps of $1.60 for Q4 2025.
Did Acadia Pharmaceuticals beat estimates in Q4 2025?
Revenue missed the consensus estimate of $292.8M by $8.8M. EPS beat the consensus estimate of $0.14 by $1.46.
How did Acadia Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 9.4% from $259.6M a year earlier and eps grew 841.2% from $0.17.
Where can I find Acadia Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-071674) and the 10-K periodic report (0001193125-26-072519) directly on SEC EDGAR. The filing index links above go to sec.gov.